
Sequana Medical
Total Raised
$60.5MInvestors Count
9Deal Terms
2Funding, Valuation & Revenue
5 Fundings
Sequana Medical has raised $60.5M over 5 rounds.
Sequana Medical's latest funding round was a IPO for $31.04M on February 11, 2019.
Sequana Medical's latest post-money valuation is from February 2019.
Sign up for a free demo to see Sequana Medical's valuations in February 2019 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
2/11/2019 | IPO | $31.04M | 3 | |||
10/23/2015 | Series C - II | |||||
4/28/2014 | Series C | |||||
4/6/2011 | Series B | |||||
Other Investors |
Date | 2/11/2019 | 10/23/2015 | 4/28/2014 | 4/6/2011 | |
|---|---|---|---|---|---|
Round | IPO | Series C - II | Series C | Series B | Other Investors |
Amount | $31.04M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 3 |
Sequana Medical Deal Terms
2 Deal Terms
Sequana Medical's deal structure is available for 2 funding rounds, including their IPO from February 11, 2019.
Round | IPO | Series B |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series B |
Sequana Medical Investors
9 Investors
Sequana Medical has 9 investors. Capricorn Partners invested in Sequana Medical's Series C - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/6/2011 | 10/23/2015 | 3 Series B, Series C (2014), Series C - II (2015) | Venture Capital | Belgium | ||
Venture Capital | United Kingdom | |||||
Venture Capital | Norway | |||||
Venture Capital | Switzerland | |||||
Venture Capital | Switzerland |
First funding | 4/6/2011 | ||||
|---|---|---|---|---|---|
Last Funding | 10/23/2015 | ||||
Investor | |||||
Rounds | 3 Series B, Series C (2014), Series C - II (2015) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Venture Capital | Venture Capital |
Location | Belgium | United Kingdom | Norway | Switzerland | Switzerland |
Compare Sequana Medical to Competitors

FloShield develops a system that includes a sheath directing CO2 gas to the tip of a laparoscope, utilizing Vortex Barrier Technology to protect the lens from condensation, debris, and smoke. This design reduces the need to remove the scope during operations. The products are compatible with both traditional and robotic laparoscopes. It was founded in 2009 and is based in Cupertino, California.
Coromedic focuses on devices and techniques for minimally invasive coronary surgery within the medical devices industry. The company provides automatic proximal and distal anastomosis for bypass surgeries and a mammary artery harvester for artery harvesting. It is based in Israel.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

MicroTransponder focuses on developing medical devices in the neuromodulation domain for chronic neurological conditions. It offers the Vivistim Paired VNS System, which stimulates the vagus nerve during rehabilitation therapy in patients with chronic ischemic stroke. It is intended for use in patients with upper extremity motor deficits following a stroke. It was founded in 2007 and is based in Austin, Texas.
Cardious is a medical device company organized to develop and commercialize the AvA Aortic Valve Bypass Graft System for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.
Orthonicsis a company created through Georgia Tech's Venturlab program. Orthonics is developing biomaterials for orthopaedic tissue engineering applications. The company's core technology relates to biomaterials that permit in-growth and adhesion of bone and cartilage tissues. Initial applications will be spinal disc replacement and as aspinal disc annulus patch.
Loading...

